![History of PD-1 research. Abbreviations: FIM, first in man; approved,... | Download Scientific Diagram History of PD-1 research. Abbreviations: FIM, first in man; approved,... | Download Scientific Diagram](https://www.researchgate.net/publication/315976717/figure/fig2/AS:613923275411502@1523382123664/History-of-PD-1-research-Abbreviations-FIM-first-in-man-approved-FDA-approved-NCT.png)
History of PD-1 research. Abbreviations: FIM, first in man; approved,... | Download Scientific Diagram
![Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial | Nature Medicine Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig1_HTML.png)
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial | Nature Medicine
![Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer - Annals of Oncology Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/37209b45-e568-4071-9c3f-5efa01b92396/gr1_lrg.jpg)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer - Annals of Oncology
![Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC) - Clinical Trials Arena Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC) - Clinical Trials Arena](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2l-image-151.jpg)
Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC) - Clinical Trials Arena
![Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial - Journal of Thoracic Oncology Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8b0490dd-a749-4ead-ac39-e90279f443e4/gr1_lrg.jpg)
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial - Journal of Thoracic Oncology
![Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial - Clinical Lung Cancer Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial - Clinical Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/6b283c9b-ad65-444a-8164-affacba9f1ca/gr1.jpg)
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial - Clinical Lung Cancer
![Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) | Journal for ImmunoTherapy of Cancer Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/10/2/e004025/F1.large.jpg)
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) | Journal for ImmunoTherapy of Cancer
![Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial - European Urology Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/c9462e36-e591-45c5-940f-50c9986472b1/gr1.jpg)
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial - European Urology
![Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7c360474-713b-4144-8659-563921692a7b/gr1.gif)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
![Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China | Journal of Hematology & Oncology | Full Text Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13045-017-0506-z/MediaObjects/13045_2017_506_Fig1_HTML.gif)
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China | Journal of Hematology & Oncology | Full Text
![A clinical trial to compare atezolizumab with a placebo in people with head and neck cancer who are at a high risk of their cancer returning or getting worse after completion of A clinical trial to compare atezolizumab with a placebo in people with head and neck cancer who are at a high risk of their cancer returning or getting worse after completion of](https://roche63-h.assetsadobe2.com/is/image//content/dam/patient-platform/ctd-designs/global-platform/4751-%20Ashfield%2032.%20CTD%20IMvoke010%20infographic_1116742_LLv1.jpg?$pp-text-image$)
A clinical trial to compare atezolizumab with a placebo in people with head and neck cancer who are at a high risk of their cancer returning or getting worse after completion of
![Anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab currently... | Download Scientific Diagram Anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab currently... | Download Scientific Diagram](https://www.researchgate.net/publication/327840656/figure/fig5/AS:674379453190149@1537795999261/Anti-PD-L1-antibodies-atezolizumab-avelumab-and-durvalumab-currently-in-clinical.png)
Anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab currently... | Download Scientific Diagram
![Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials - European Journal of Cancer Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/9d19693a-511d-4721-943b-c5c4876a715c/gr1.jpg)
Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials - European Journal of Cancer
![Selection of ongoing trials of pembrolizumab or atezolizumab in TNBC... | Download Scientific Diagram Selection of ongoing trials of pembrolizumab or atezolizumab in TNBC... | Download Scientific Diagram](https://www.researchgate.net/publication/337511173/figure/tbl2/AS:829303948316674@1574732877205/Selection-of-ongoing-trials-of-pembrolizumab-or-atezolizumab-in-TNBC-source.png)
Selection of ongoing trials of pembrolizumab or atezolizumab in TNBC... | Download Scientific Diagram
![Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial - The Lancet Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c0a4a03a-9bf3-423a-b556-9b9324364c65/gr1.gif)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial - The Lancet
![Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial - The Lancet Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cdbcc4ad-94ee-4aea-ab99-a8924cff77d7/gr3.jpg)